Benzinga | Nov 4, 2021 07:24AM EDT

Barclays Maintains Overweight on BioCryst Pharmaceuticals, Lowers Price Target to $17

Barclays analyst Gena Wang maintains BioCryst Pharmaceuticals (NASDAQ:BCRX) with a Overweight and lowers the price target from $21 to $17.